Jean-Marie Dru, Chairman of TBWA\Worldwide, Sharon Callahan, CEO of TBWA\WorldHealth, and Robin Shapiro, Global President of TBWA\WorldHealth, unveiled a new vision for TBWA\WorldHealth London.

This whitepaper assesses the current state of the large molecule sector, and how it may be able to learn from the small molecule industry in terms of its supply chain support infrastructure, as well as its acquisition of staff and the adoption of PAT.

Amgen announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with Remicade (infliximab) in patients with moderate-to-severe rheumatoid arthritis.

Ogilvy CommonHealth Worldwide, a WPP Health & Wellness company, announced twelve promotions and three new hires to meet the growing demands at the network’s New Jersey-based medical education group.

A full-service network, Intouch Group serves as the parent organization for six affiliates and represents Intouch Solutions’ diverse suite of capabilities and depth of service offerings.

The U.S. FDA accepted a New Drug Application and granted Priority Review for Genentech’s baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older.

This free webinar is designed for childhood cancer advocates who want to learn more about effective advocacy practices in local communities and states.

The European Commission granted Marketing Authorization for Gilead Sciences Inc.’s Biktarvy as a once-daily single tablet regimen for the treatment of HIV-1 infection.

BBK Worldwide – for 35 years on the crest of the wave with regard to the development and evolution of the patient recruitment industry – announced its new marketplace position as The Patient Experience Company.

Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.